Pemetrexed: the key role and clinical application of antineoplastic drugs

Pemetrexed is a chemotherapy drug widely used in the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. It is an anti-metabolite anti-tumor agent. This article will cover its mechanism of action, indications, clinical research and manufacturers to help readers fully understand this drug. The main contents include:1) Pharmacological properties of pemetrexed;2) Indications and combination medication regimens;3) Clinical efficacy and safety data;4) Major domestic and foreign manufacturers. Through structured analysis, it provides practical reference for medical practitioners and patients.

Pharmacological properties and mechanism of action

Pemetrexed blocks the DNA synthesis and repair of tumor cells by inhibiting a variety of folate-dependent enzymes (such as thymidylate synthase and dihydrofolate reductase), thereby inhibiting their proliferation. Studies have shown that it has significant efficacy in non-small cell lung cancer, especially when combined with platinum drugs (such as cisplatin). It is worth noting that patients need to supplement folic acid and vitamin B12 before taking the drug to reduce the risk of hematological toxicity. American Society of Clinical Oncology (ASCO) guidelines list it as a first-line treatment option for advanced NSCLC.

Indications and combination treatment options

pemetrexedMain indicationsIncludes non-squamous non-small cell lung cancer and malignant pleural mesothelioma. In clinical practice, it is often combined with cisplatin or carboplatin to form a standard chemotherapy regimen. For example, the KEYNOTE-189 study showed that pemetrexed combined with pembrolizumab (a PD-1 inhibitor) can significantly extend the progression-free survival of patients. In addition, monotherapy has also proven effective in patients who cannot tolerate platinum-based drugs. The dosage is usually adjusted based on body surface area, and medical advice must be strictly followed.

Clinical efficacy and safety data

According to multiple phase III clinical trials, the objective response rate (ORR) of pemetrexed in non-squamous NSCLC can reach 30%-40%, and the median survival time is about 12 months. Common adverse reactions include bone marrow suppression, fatigue and gastrointestinal reactions, but most are controllable. The following table lists key clinical data:

Manufacturer and market overview

The original drug of pemetrexed was developed by Eli Lilly and its trade name isAlimta. Many domestic pharmaceutical companies have passed the consistency evaluation of generic drugs, including Hansoh Pharmaceuticals (Pulaile), Qilu Pharmaceuticals (Saizhen), etc. The following table lists the major manufacturers:

Summary and Outlook

As an important drug for anti-tumor treatment, pemetrexed has significantly improved the survival prognosis of patients with non-small cell lung cancer by precisely inhibiting tumor metabolic pathways. The popularity of its combination regimens and generic drugs has further improved accessibility. In the future, with the combination of targeted therapy and immunotherapy, the application scenarios of pemetrexed may be further expanded. Medical workers need to pay attention to individualized medication strategies and balance efficacy and safety.

Citing sources: 1. American Society of Clinical Oncology (ASCO) Guidelines (2022 Edition) 2. KEYNOTE-189 Study (New England Journal of Medicine) 3. National Medical Products Administration (NMPA) Generic Drug Catalog 4. Official product instructions of Eli Lilly, Hansoh Pharmaceuticals, and Qilu Pharmaceuticals